Hemispherian announced the initiation of a first-in-human Phase 1/2a clinical trial of GLIX1 in patients with recurrent and progressive glioblastoma and other high-grade gliomas. The study is being conducted in collaboration with BioLineRx (BLRX).
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLRX:
- BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target
- BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma
- BioLineRx initiates Phase 1/2a study of GLIX1
- Options Volatility and Implied Earnings Moves Today, March 23, 2026
- Options Volatility and Implied Earnings Moves This Week, March 23 – March 27, 2026